# A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life

> **NCT03774875** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 277 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03774875
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-11-03
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03774875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03774875, "A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03774875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*